Follow the Kalaris Therapeutics, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Market capitalisation: €99.3m. The latest transaction was disclosed on 22 May 2026 (Acquisition). Among the most active insiders: AKKARAJU SRINIVAS. Every trade is accessible without an account.
12
Insider Decl.
n/a
Thresholds
€5m
2 ops.
Buy Volume
€18,657
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Kalaris Therapeutics, Inc. Strong Buy (bullish), based on 7 analysts. Average price target: US$18.71.
27Σ signal
Buys €5m€18,657 Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Kalaris Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative treatments for serious diseases. It is listed on NASDAQ under the ticker XNAS.